Partnership17 Mar 2025, 09:53 pm
Shilpa Medicare's Subsidiary Enters Binding Term Sheet with mAbTree Biologics AG for Co-development of a New Biological Entity
AI Summary
Shilpa Biologicals Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited, has entered into a binding Term Sheet with mAbTree Biologics AG based out of Basel, Switzerland. The agreement is for the development, manufacture, marketing and sale of a New Biological Entity (NBE). Shilpa Biologicals will support both development and long-term commercial supply with GMP manufacturing. The partnership aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation and generation of strong immune responses against tumours.
Key Highlights
- Shilpa Biologicals Private Limited has entered into a binding Term Sheet with mAbTree Biologics AG for co-development of a New Biological Entity (NBE)
- The NBE is a novel biologic asset for immuno-oncological applications
- Shilpa Biologicals will support both development and long-term commercial supply with GMP manufacturing
- The partnership aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein
- The novel therapy represents a new frontier in immuno-oncology, with the potential to expand treatment for patients who do not benefit from current immunotherapy options